ClinicalTrials.gg
Enrolling by invitationNCT07298486Updated Nov 10, 2026

Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS

An interventional study of Robotic Glove Use in Amyotrophic Lateral Sclerosis (ALS), sponsored by Nova Southeastern University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Nova Southeastern University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
271st of 307
5 · median 33
Started
2026
with 32 others
No phase
82 of 440
32 open now
Primary completion
2027-01
later than 36 of 128 live
Registered
413th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 271st largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 82 with no phase, reaches primary completion later than 36 of the 128 other live ones, and was the 413th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the impact of robotic glove use on quality of life, grip strength and fine motor control in participants with Amyotrophic Lateral Sclerosis (ALS). This will provide valuable insights into how an assistive technology intervention can influence functional ability in daily tasks and enhance overall well-being in individuals impacted by ALS.

Participants will attend 3 in-person clinic visits (BASE, 4 week and 8 week visit) and 2 Telehealth visits (occurring 24 hours after BASE and 4 week visit). The in-person clinic visits will include assessments by either a physical or occupational therapist, followed by assessments and scoring of grip strength, various fine motor strength assessments of affected hand, fine motor coordination assessment of the affected hand and various quality of life scales.

The participant will be fitted and measured for the appropriately sized robotic glove. Once the fit is confirmed, both the participant and caregiver will receive education on how to don and doff the glove, power it on and off, and follow the study protocol. Once they demonstrate understanding and independence with these steps, the intervention will begin.

The robotic glove intervention consists of either the participant or caregiver donning the glove and powering it on. A timer will be set for 20 minutes. The participant will sit comfortably at a table with their elbow supported on the table. The PI and/or member of the study team will be present throughout the 20 minute session to monitor for discomfort, fatigue or any additional patient reported symptoms. Once the time is complete, the robotic glove will be powered off and the glove removed. The participant and caregiver will be instructed to perform this one time daily, for 5 days per week for a total of 8 weeks. The PI and study team members will be available for any questions via iPhone or e-mail throughout this time period.

The Telehealth visits will consist of synchronous video and audio via the Zoom application. The PI and/or study team members will monitor the set up, application and powering on of the Robotic Glove. The treatment of 20 minutes will be monitored and any questions the participant or caregiver have will be answered. This visit's goal is to ensure compliance and proper application of the robotic glove.

Read the detailed description

The primary aim of this study is to determine the impact of robotic glove use on quality of life, grip strength and fine motor control in participants with ALS. The study population includes 5 participants with a diagnosis of ALS, aged 18-99.

Once consent and enrollment is complete, the participant will be measured for their robotic glove size on day of enrollment. The robotic glove is a rehabilitation device that fits over the participants fingers and is secured through velcro straps. It delivers passive range of motion through an air pump that facilitates finger flexion and extension.

Measurements will be performed with a standard tape measure. The following 3 measurements will be taken of the participants affected hand:

  1. Hand width: determined by the base of the 1st metacarpal to distal end of 5th metacarpal
  2. Hand length: determined by lunate to distal end of distal phalanx of digit 3
  3. Middle finger circumference: determined by the circumference of the distal end of proximal phalanx of digit

The proper size robotic glove will be obtained and the BASE clinic visit will be scheduled.

Each participant will then attend three (3) in=person clinic visits and participate in two (2) telehealth visits. The clinic visits will take place at three time points: baseline (BASE), 4 weeks after the start date (4W), and post-intervention at 8 weeks (POST). The BASE visit is expected to last 60 minutes. The 4W and POST visits are expected to last 30 minutes.

Outcome measures that will be assessed at each in person clinic visit include:

  1. Amyotrophic Lateral Sclerosis Quality of Lift Short Form (ALS QOL short form)
  2. EuroQOL-5D (EQ-5D)
  3. Grip Strength
  4. 9 Hole PEG test
  5. Tip-to-Tip pinch strength
  6. Palmar pinch strength
  7. Key pinch strength
  8. Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) and its Gross motor and fine motor sub-scales (GMS) (FMS)

BASE visit:

The Base visit will consist of above mentioned assessments followed by training of both patient and caregiver on how to don and doff the robotic glove. The PI and/or study team will complete the training, followed by monitoring the patient and caregiver successfully applying the Robotic glove. The PI will manually set the robotic glove for passive mode with a 6 second on time and 6 second off time. Once the participant and caregiver are able to successfully demonstrate application and removal of the robotic glove, including powering on and off the robotic glove, the robotic glove intervention will commence.

ROBOTIC GLOVE INTERVENTION: The participant or caregiver will don the robotic glove and power on the device. A timer will be set for 20 minutes. The participant will sit comfortably at a table with their elbow supported on the table. The PI and/or study team member will be present throughout the 20 minute session to monitor for discomfort, fatigue or any additional patient reported symptoms. Once the time is complete, the robotic glove will be powered off and the glove removed.

The participant and caregiver will be instructed to perform this one time daily, for 5 days per week for a total of 8 weeks. The PI and Co-PI will be available for any questions via iPhone or e-mail throughout this time period.

Telehealth Visit #1 (TH1):

This visit will commence on day 2 and will take approximately 30 minutes. A telehealth appointment will be set up with the participant and their caregiver 24 hours after the baseline visit. This will consist of synchronous video and audio via the Zoom application. The PI and/or Co-PI will monitor the set up, application and powering on of the Robotic Glove. The treatment of 20 minutes will be monitored and any questions the participant or caregiver have will be answered. This visit's goal is to ensure compliance and proper application of the robotic glove.

4W visit: The 4W visit will consist of above mentioned assessments (#1-8) as previously described in the BASE visit and will be completed in person. This is expected to last 30 minutes

Telehealth Visit #2 (TH2):

This visit will commence 24 hours after visit 4W and will mimic TH1.

POST visit:

This will occur during week 8 once all 40 intervention sessions have been completed. The participant and caregiver will be brought in to the clinic and assessments 1-8 will be completed.

This will conclude the study intervention.

Weekly telephone calls will be conducted by study personnel to ensure compliance with the protocol, the robotic glove is working properly and answer any questions the participant or caregiver may have.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
  • Motor Neuron Disease
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of clinically possible, probable or definite amyotrophic lateral sclerosis by the treating neurologist
  • Have a caregiver that is willing and present to assist with application of robotic glove
  • Reports fine motor deficits or grip strength deficits in at least 1 hand
  • Demonstrates > or = 3 lbs. of Grip strength as measured by a dynamometer on affected hand AND/OR Demonstrates Fine motor deficits and has > or = 1 lb. of pinch strength (tip to tip, three jaw chuck, or lateral key pinch) as measured by pinch gauge dynamometer
  • Demonstrates a loss of at least 3 lbs. of Grip strength OR 1lb. of pinch strength over a minimum of 1 month period in affected hand
  • Stable dose of efficacious medications for 30 days.

Exclusion criteria

Exclusion Criteria:

  • History of Rheumatoid Arthritis
  • History of Depuytren's contracture
  • Open wound at affected hand where robotic glove will be placed
  • History of Trigger Finger
  • Complete loss of sensation at the affected hand where robotic glove will be placed
  • History of Carpal Tunnel Syndrome
  • Prior or current use of robotic glove
  • Active physical or occupational therapy treatment interventions on affected hand
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Robotic Glove Intervention

    Participants with initiate robotic glove use 5 days / week , 1x/day for 20 minutes

    Device: Robotic Glove Use

Interventions

  • DeviceRobotic Glove Use

    The participant or caregiver will don the robotic glove and power on the device. A timer will be set for 20 minutes. The participant will sit comfortably at a table with their elbow supported on the table. When the time is complete, the robotic glove will be powered off and the glove removed. The PI and/or study team will be present throughout the first 2 sessions and 2 sessions midway into the 8 week study period to monitor for discomfort, fatigue or any additional patient reported symptoms. The participant will complete a total of 40 intervention sessions. Weekly telephone calls will be conducted by study team members to ensure compliance with the protocol, the robotic glove is working properly and answer any questions the participant or caregiver may have.

06

What researchers measure

Primary outcomes

  1. ALS-Specific Quality of Life Questionnaire - Short Form

    is a validated, disease-specific questionnaire designed to assess quality of life in individuals with ALS. It provides a concise measure of key domains such as emotional well-being, physical symptoms, social interaction, and existential concerns. The short-form version reduces patient burden while maintaining strong reliability and sensitivity to changes in health status over time.

    Time frame: Baseline, 4 weeks, 8 weeks

Secondary outcomes

  1. EuroQOL-5D

    a standardized, patient-reported outcome measure used to assess health-related quality of life. It evaluates five key dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated by level of severity. It also includes a visual analog scale (VAS) where patients rate their overall health from 0 to 100.

    Time frame: Baseline, 4 weeks and 8 weeks

  2. Grip Strength

    Grip strength is measured in pounds utilizing a handheld dynamometer. The participant will be asked to perform maximum grip strength by squeezing a handheld dynamometer over 3 seconds, 3 reps and the average will be taken.

    Time frame: Baseline, 4 weeks, 8 weeks

  3. Finger tip to tip pinch strength

    Fingertip-to-tip pinch strength is measured by having the patient press the tip of their thumb and the tip of their index finger together against a pinch gauge. The patient applies maximal pressure, and the device records the force generated. The participant will be asked to complete this 3 times and the average will be taken.

    Time frame: baseline, 4 weeks, 8 weeks

  4. Palmar pinch strength

    Palmar pinch strength (also called three-jaw chuck pinch) measures the force generated when the thumb presses against the pads of the index and middle fingers. Using a pinch gauge, the participant is asked to squeeze as firmly as possible. Three trials are performed, and the average is recorded. This measure reflects the ability to perform everyday tasks requiring precision and control, such as holding a key, buttoning clothes, or picking up small objects.

    Time frame: Baseline, 4 weeks and 8 weeks

  5. Key Pinch Strength

    This test reflects functional hand strength used in tasks like turning a key, gripping a card, or opening a door. Using a pinch gauge, the participant is asked to place the gauge between the thumb pad and side of the index finger and pinch as hard as possible. 3 trials are performed and the average force is recorded.

    Time frame: Baseline, 4 weeks and 8 weeks

  6. 9 Hole PEG test

    A standardized assessment of finger dexterity and fine motor coordination. The participant is asked to place nine pegs into nine holes and then remove them as quickly as possible, using their affected hand. The time taken to complete the task is recorded. Faster times indicated improved manual dexterity.

    Time frame: Baseline, 4 weeks and 8 weeks

  7. Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)

    It evaluates 12 items across four domains: bulbar (speech, swallowing), fine motor (handwriting, dressing), gross motor (walking, climbing stairs), and respiratory function (breathing, dyspnea). Each item is scored from 0 (worst) to 4 (normal), giving a total score from 0 to 48, with higher scores indicating better function. It's used to track disease progression and assess response to treatments.

    Time frame: Baseline, 4 weeks and 8 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Felgoise SH, Feinberg R, Stephens HE, Barkhaus P, Boylan K, Caress J, Clawson LL, Elman L, Goutman SA, Mccluskey L, Russell J, Tiryaki E, Weiss M, Simmons Z. Amyotrophic lateral sclerosis-specific quality of life-short form (ALSSQOL-SF): A brief, reliable, and valid version of the ALSSQOL-R. Muscle Nerve. 2018 Nov;58(5):646-654. doi: 10.1002/mus.26203. Epub 2018 Oct 19. PubMed 30028537 ↗
  • Hayden CD, Murphy BP, Hardiman O, Murray D. Measurement of upper limb function in ALS: a structured review of current methods and future directions. J Neurol. 2022 Aug;269(8):4089-4101. doi: 10.1007/s00415-022-11179-8. Epub 2022 May 25. PubMed 35612658 ↗
  • Wang T, Liu Z, Gu J, Tan J, Hu T. Effectiveness of soft robotic glove versus repetitive transcranial magnetic stimulation in post-stroke patients with severe upper limb dysfunction: A randomised controlled trial. Front Neurol. 2023 Jan 11;13:887205. doi: 10.3389/fneur.2022.887205. eCollection 2022. PubMed 36712422 ↗
  • Yamakawa I, Yamada A, Sonoda Y, Wakita K, Nishioka T, Harada Y, Ogawa N, Kitamura A, Sanada M, Tani T, Imai S, Urushitani M. Occupational therapy using a robotic-assisted glove ameliorates finger dexterity and modulates functional connectivity in amyotrophic lateral sclerosis. J Clin Neurosci. 2023 Jan;107:144-149. doi: 10.1016/j.jocn.2022.11.004. Epub 2022 Nov 18. PubMed 36411175 ↗

Individual participant data

Plan to share: Yes — All 5 participants baseline assessments, 4 week assessments and post assessments will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified IPD will be available 12 months after publication of the primary results and for a period of 5 years.

Access criteria: De-identified IPD will be shared with qualified researchers upon reasonable request, subject to review by the study investigators and execution of a data use agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 11 months is below that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Jan 2027 and completion Jul 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Dec 23, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Jan 30, 2027was Jul 2026
CompletionEst.
Jan 30, 2027was Jul 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2026→Jan 30, 2027
Nov 10, 2026
Study completion
Jul 30, 2026→Jan 30, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jul 30, 2026→Jan 30, 2027
    Study completion Jul 30, 2026→Jan 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298486
Lead sponsor
Nova Southeastern University
Responsible party
Kayla Chomko (Rehabilitation Director, Nova Southeastern University) — Principal investigator
First posted
Dec 23, 2025
Start date
Feb 9, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Kayla Chomko, PT, DPT
principal investigator · Nova Southeastern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion